Importantly, the efficacy was further enhanced when combined with the FLT3 inhibitor gilteritinib, which upregulates NKG2D ligand expression on AML cells via NFκB2/Rel B signaling pathway. This evidence concerns the gene KLRK1 and acute myeloid leukemia.